MAPK/ERK SIGNALING IN GLIOMAS MODULATES INTERFERON RESPONSES, PROMOTES TUMOR-MICROGLIA CROSSTALK, AND CONFERS SUSCEPTIBILITY TO ANTI-PD-1 AND ANTI-CTLA-4 IMMUNOTHERAPY

被引：0
|
作者：
Kim, Kwang-Soo [1 ]
Zhang, Junyi [2 ]
Dmello, Crismita [1 ]
Grabis, Elena [2 ]
Arrieta, Victor [1 ]
Habashy, Karl [1 ]
Zhao, Junfei [3 ]
Duffy, Joseph [1 ]
Gould, Andrew [1 ]
Chen, Li [1 ]
Balyasnikova, Irina [1 ]
Canoll, Peter [3 ]
Sims, Peter [3 ]
Rabadan, Raul [3 ]
Lee-Chang, Catalina [1 ]
Heiland, Dieter Henrik [2 ]
Sonabend, Adam [1 ]
机构：
[1] Northwestern Univ, Chicago, IL USA
[2] Univ Freiburg, Freiburg, Germany
[3] Columbia Univ, New York, NY USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NOAE165.02
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity
    Harui, Airi
    McLachlan, Sandra M.
    Rapoport, Basil
    Zarembinski, Thomas, I
    Roth, Michael D.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (09) : 1737 - 1749
  • [42] Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity
    Airi Harui
    Sandra M. McLachlan
    Basil Rapoport
    Thomas I. Zarembinski
    Michael D. Roth
    Cancer Immunology, Immunotherapy, 2020, 69 : 1737 - 1749
  • [43] A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort
    Chae, Young Kwang
    Othus, Megan
    Patel, Sandip Pravin
    Ohr, James P.
    Worden, Francis P.
    Suga, Jennifer M.
    Naing, Aung
    Fenton, Sarah E.
    Kang, Hyunseok
    Gurung, Sewan
    McLeod, Christine M.
    Giles, Francis J.
    Chen, Helen X.
    Sharon, Elad
    Mayerson, Edward
    Plets, Melissa
    Ryan, Christopher
    Blanke, Charles D.
    Kurzrock, Razelle
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer
    Lin, Mei-Chun
    Chuang, Ya-Ting
    Wu, Hsin-Yi
    Hsu, Chia-Lang
    Lin, Neng-Yu
    Huang, Min-Chuan
    Lou, Pei-Jen
    MOLECULAR ONCOLOGY, 2024, 18 (02) : 350 - 368
  • [45] A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort
    Chae, Young Kwang
    Othus, Megan
    Patel, Sandip Pravin
    Zalupski, Mark
    Kasi, Anup
    Khalil, Maged
    Kalyan, Aparna
    Polite, Blase
    Fenton, Sarah
    Gurung, Sewan
    McLeod, Christine M.
    Giles, Francis
    Chen, Helen X.
    Sharon, Elad
    Mayerson, Edward
    Plets, Melissa
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    CANCER RESEARCH, 2020, 80 (16)
  • [46] HIGH ENDOTHELIAL VENULES CONTROL THE JOURNEY OF STEM-LIKE CD8+ T CELLS FROM LYMPH NODE TO TUMOR DURING CANCER IMMUNOTHERAPY WITH COMBINED ANTI-PD-1 PLUS ANTI-CTLA-4 ANTIBODIES
    Blanchard, Lucas
    Vina, Estefania
    Tarroux, Dorian
    Lefrancais, Emma
    Ortega, Nathalie
    Girard, Jean-Philippe
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A530 - A530
  • [47] A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort
    Chae, Young Kwang
    Othus, Megan
    Patel, Sandip Pravin
    Wilkinson, Kelly J.
    Whitman-Purves, Emily M.
    Lea, Jayanthi
    Schallenkamp, John M.
    Adra, Nabil
    Appleman, Leonard J.
    Alden, Mitchell
    Pepin, Jessica Thomes
    Ellerton, John A.
    Poklepovic, Andrew
    Walter, Adam
    Rampurwala, Murtuza M.
    Robinson, William R.
    Chung, Liam Il-Young
    McLeod, Christine M.
    Chen, Helen X.
    Sharon, Elad
    Streicher, Howard
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    CANCER RESEARCH, 2023, 83 (08)
  • [48] Dual checkpoint inhibition using anti-PD-1 and anti-CTLA-4 in combination with entinostat increases treatment efficacy and decreases suppressive signaling between myeloid cells and T cells in breast-to-lung metastasis
    Gonzalez, Edgar
    Kreger, Jesse
    Liu, Yingtong
    Baugh, Aaron
    Jang, Julie
    Al-Zubeidy, Batul
    Danilova, Ludmila
    Shin, Sarah M.
    Barbetta, Arianna
    Bangerth, Sara-Elisa B.
    Jacobo, Matthew
    Castanon, Sofi
    Stearns, Vered
    Connolly, Roisin M.
    Ho, Won
    Emaumaullee, Juliet
    MacLean, Adam
    Roussos-Torres, Evanthia T.
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [49] Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report
    Nakashima, Chiho
    Kuwahara, Yuki
    Kitamura, Syo
    Kai, Keita
    Hiratsuka, Masafumi
    Kajiwara, Kokoro
    Komiya, Natsuko
    Ogusu, Shinsuke
    Kimura, Shinya
    Sueoka-Aragane, Naoko
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2024, 14
  • [50] Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc.R engagement and type I interferon signaling (Oct, 10.1038/s43018-022-00447-1, 2022)
    Yofe, Ido
    Landsberger, Tomer
    Yalin, Adam
    Solomon, Isabelle
    Costoya, Cristobal
    Demane, Dafne Franz
    Shah, Mansi
    David, Eyal
    Borenstein, Chamutal
    Barboy, Oren
    Matos, Ignacio
    Peggs, Karl S.
    Quezada, Sergio A.
    Amit, Ido
    NATURE CANCER, 2022, 3 (11) : 1404 - 1404
12345